Low-risk (arm 1) and high-risk (arm 2) patient and unit characteristics in recipients of the TREO/FLU/TBI-conditioning regimen prior to CBT
| Characteristic . | Total, N = 130 . | Arm 1,* n = 66 . | Arm 2,* n = 64 . |
|---|---|---|---|
| Female, n (%) | 69 (53) | 36 (53) | 33 (52) |
| Age, median (range), y | 45 (0.6-65) | 47 (0.6-65) | 43 (2-64) |
| Weight, median (range), kg | 70 (7-131) | 74 (7-131) | 66 (11-112) |
| Race, n (%) | |||
| White | 63 (48) | 38 (58) | 35 (54) |
| Nonwhite | 67 (52) | 28 (42) | 29 (46) |
| HCT-CI, median (range) | 2 (0-6) | 2 (0-5) | 2 (0-6) |
| CMV serostatus positive, n (%) | 85 (65) | 39 (63) | 46 (74) |
| Diagnosis, n (%) | |||
| AML | 63 (49) | 38 (57) | 25 (40) |
| ALL | 37 (28) | 24 (37) | 13 (19) |
| Byphenotypic | 2 (1) | 1 (1) | 1 (1) |
| MDS | 25 (20) | 3 (4) | 22 (35) |
| Myeloproliferative | 3 (2) | — | 3 (5) |
| Status at time of HCT, n (%) | |||
| MRD+ | 36 (27) | 10 | 26 |
| CR2 or higher | 46 (36) | 24 | 22 |
| Prior transplantation, n (%) | 35 (26) | 20 (30) | 15 (27) |
| Autologous | 2 | 1 (7) | 1 (7) |
| Allogeneic | 33 | 19 (93) | 14 (93) |
| No. of units received, n (%) | |||
| 1 | 31 (24) | 17 (25) | 14 (23) |
| 2 | 99 (76) | 50 (75) | 49 (77) |
| Overall CD34, median (range),† ×106/ kg | 0.32 (0.04-2.44) | 0.32 (0.04-2.44) | 0.32 (0.09-1.01) |
| Overall TNC, median (range),† ×107/kg | 5.5 (3.3-25.0) | 5.5 (3.3-25.0) | 5.5 (3.5-11.8) |
| TNC per unit in dCBT, n = 99, median (range), ×107/kg | |||
| Unit 1 | 3.1 (1.5-6) | 3.1 (1.5-4.9) | 3.1 (1.5-6.0) |
| Unit 2 | 2.51 (1.5-10.5) | 2.51 (1.5-10.5) | 2.52 (1.6-6.3) |
| HLA matching to recipients, n (%)‡ | |||
| 6 of 6 | 5 (3) | 3 (4) | 2 (3) |
| 5 of 6 | 42 (35) | 25 (38) | 17 (27) |
| 4 of 6 | 83 (62) | 39 (58) | 44 (70) |
| Institution, n (%) | |||
| FHCRC | 120 (86) | 61 (87) | 59 (92) |
| Colorado | 7 (10) | 4 (9) | 3 (6) |
| OHSU | 3 (4) | 2 (4) | 1 (2) |
| Graft failure, n (%) | 7 (5) | 2 (3) | 5 (8) |
| Characteristic . | Total, N = 130 . | Arm 1,* n = 66 . | Arm 2,* n = 64 . |
|---|---|---|---|
| Female, n (%) | 69 (53) | 36 (53) | 33 (52) |
| Age, median (range), y | 45 (0.6-65) | 47 (0.6-65) | 43 (2-64) |
| Weight, median (range), kg | 70 (7-131) | 74 (7-131) | 66 (11-112) |
| Race, n (%) | |||
| White | 63 (48) | 38 (58) | 35 (54) |
| Nonwhite | 67 (52) | 28 (42) | 29 (46) |
| HCT-CI, median (range) | 2 (0-6) | 2 (0-5) | 2 (0-6) |
| CMV serostatus positive, n (%) | 85 (65) | 39 (63) | 46 (74) |
| Diagnosis, n (%) | |||
| AML | 63 (49) | 38 (57) | 25 (40) |
| ALL | 37 (28) | 24 (37) | 13 (19) |
| Byphenotypic | 2 (1) | 1 (1) | 1 (1) |
| MDS | 25 (20) | 3 (4) | 22 (35) |
| Myeloproliferative | 3 (2) | — | 3 (5) |
| Status at time of HCT, n (%) | |||
| MRD+ | 36 (27) | 10 | 26 |
| CR2 or higher | 46 (36) | 24 | 22 |
| Prior transplantation, n (%) | 35 (26) | 20 (30) | 15 (27) |
| Autologous | 2 | 1 (7) | 1 (7) |
| Allogeneic | 33 | 19 (93) | 14 (93) |
| No. of units received, n (%) | |||
| 1 | 31 (24) | 17 (25) | 14 (23) |
| 2 | 99 (76) | 50 (75) | 49 (77) |
| Overall CD34, median (range),† ×106/ kg | 0.32 (0.04-2.44) | 0.32 (0.04-2.44) | 0.32 (0.09-1.01) |
| Overall TNC, median (range),† ×107/kg | 5.5 (3.3-25.0) | 5.5 (3.3-25.0) | 5.5 (3.5-11.8) |
| TNC per unit in dCBT, n = 99, median (range), ×107/kg | |||
| Unit 1 | 3.1 (1.5-6) | 3.1 (1.5-4.9) | 3.1 (1.5-6.0) |
| Unit 2 | 2.51 (1.5-10.5) | 2.51 (1.5-10.5) | 2.52 (1.6-6.3) |
| HLA matching to recipients, n (%)‡ | |||
| 6 of 6 | 5 (3) | 3 (4) | 2 (3) |
| 5 of 6 | 42 (35) | 25 (38) | 17 (27) |
| 4 of 6 | 83 (62) | 39 (58) | 44 (70) |
| Institution, n (%) | |||
| FHCRC | 120 (86) | 61 (87) | 59 (92) |
| Colorado | 7 (10) | 4 (9) | 3 (6) |
| OHSU | 3 (4) | 2 (4) | 1 (2) |
| Graft failure, n (%) | 7 (5) | 2 (3) | 5 (8) |
CR2, second complete remission; FHCRC, Fred Hutchinson Cancer Research Center; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; OHSU, Oregon Health and Science Center.
Arm 1: Low-risk patients include those who have received ≥2 cycles of multiagent chemotherapy and at least 1 cycle of therapy within the 3 months prior to CBT. Arm 2: High-risk patients include those who have received no multiagent chemotherapy or immune-suppressive chemotherapy in the 3 months prior to transplant or have received only a single induction therapy.
Prethaw median TNC and CD34+ of all units.
HLA matching reflects the lowest HLA match of the unit.